A.A. YUDENICHEVA¹, V.I. RUZOV², M.V. MINAEV³, E.N. PESHNE⁴

 ¹Volsk Regional Hospital, Volsk

²Ulyanovsk State University, Ulyanovsk

³Alliance Clinic Sviyaga LLC, Ulyanovsk

⁴City Polyclinic No. 1 named after S.M. Kirov, Ulyanovsk

Contact details:

Yudenicheva A.A. — cardiologist

Address: 22 Kommunisticheskaya St., 412909 Volsk, Russian Federation, tel.: +7-902-245-41-84, e-mail: anutka-minakova@rambler.ru

 Acute myocardial infarction (AMI) is a leading cause of cardiovascular disease (CVD)-related mortality and disability. Biomarkers can predict the course and outcome of AMI. Vaspin is an adipokine that remains a poorly studied marker in patients with cardiometabolic comorbidity.

The purpose — to evaluate serum vaspin levels during the complicated acute phase of myocardial infarction in patients with comorbid type 2 diabetes mellitus (DM).

Materials and methods. Patients with new-onset MI (n = 64) were examined, including 20 patients with type 2 DM and 44 without DM. We assessed serum vaspin levels, their relationship with acute MI complications, and glucose level dynamics.

Results. Our analysis revealed that patients with AMI had lower serum vaspin levels (<1002 pg/ml) compared to healthy individuals. We also found that patients with type 2 diabetes mellitus had lower vaspin values (0.484–2.71 pg/ml) compared to patients without diabetes (0.374–1001 pg/ml). Increased vaspin in the second group predicted a decrease in glucose levels, compared to glucose levels in the first group. Statistically significant differences were found between vaspin and hospital complications (p = 0.021), particularly ventricular extrasystole (p = 0.017).

Conclusion. Thus, the study showed a relationship between the level of serum vaspin and type 2 diabetes, as well as the course of the acute period of myocardial infarction in patients with this comorbidity.

Key words: adipokines, vaspin, biomarkers, myocardial infarction, diabetes mellitus.

REFERENCES

1. Murataliyev T.M., Zventsova V.K., Neklyudova Yu.N. et al. Gender characteristics of the course of acute myocardial infarction. Klinitsist, 2016, no. 3 (in Russ.).
2. Juge-Aubry C.E., Henrichot E., Meier C.A. Adipose tissue: a regulator of inflammation. Best Pract. Res. Clin. Endocrinol. Metab, 2005, vol. 19, pp. 547–566.
3. Zhang B., Peng W., Li H. Plasma vaspin concentrations are decreased in acute coronary syndrome, but unchanged in patients without coronary lesions. Clin. Biochem., 2013, vol. 46 (15), pp. 1520–1525. DOI: 10.1016/j.clinbiochem.2013.06.028
4. Kastl S., Katsaros K., Krychtiuk K. The adipokine vaspin is associated with decreased coronary in-stent restenosis in vivo and inhibits migration of human coronary smooth muscle cells in vitro. PLoS One, 2020, vol. 15. e0232483. DOI: 10.1371/journal.pone.0232483
5. Zhang B., Peng W., Wang K. Vaspin as a Prognostic Marker in Patients with Acute Myocardial Infarction. Heart Lung. Circ, 2016, vol. 25, pp. 257–264. DOI: 10.1016/j.hlc.2015.07.001
6. Zhou X., Chen Y., Tao Y. Serum vaspin as a predictor of adverse cardiac events in acute myocardial infarction. J Am. Heart Assoc, 2019, vol. 8 (2). e010934. DOI: 10.1161/JAHA.118.010934
7. Mankiyeva E.G., Kukhareva E.I. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Dokazatel′naya gastroenterologiya, 2023, vol. 12, no. 4, pp. 103–108 (in Russ.).
8. Chesnokova L.V., Petrov I.M., Medvedeva I.V. Endothelial function and adipokine levels in patients with non-alcoholic fatty liver disease. Klinicheskiye perspektivy gastroenterologii, gepatologii, 2014, no. 6, pp. 18–24 (in Russ.).
9. Hazlehurst J.M., Woods C., Marjot T. et al. Non-alcoholic fatty liver disease and diabetes. Metabolism, 2016, vol. 65 (8), pp. 1096–1108. DOI: 10.1016/j.metabol.2016.01.001
10. Zadionchenko V.S., Volkova N.V., Kopalova S.M. Systemic and pulmonary hypertension in chronic nonspecific lung diseases. RMZH, 1996, no. 12, p. 2 (in Russ.).
11. Syao M., Lay D., Yuy Yu. et al. Pathogenesis of pulmonary hypertension caused by left heart diseases. Front. Cardiovasc. Med, 2023, no. 10 (in Russ.). 1079142.
12. Dadabayeva N.A., Khalmukhamedov B.T., Makhmudova M.S. Trigger factors of acute left ventricular failure in patients with acute myocardial infarction. Yevraziyskiy kardiologicheskiy zhurnal, 2019, no. 2S, p. 206 (in Russ.).
13. Moiseyev V.S., Kobalava Zh.D. Ostraya serdechnaya nedostatochnost′: rukovodstvo [Acute heart failure: a guide]. Moscow: MIA, 2012. 328 p.
14. Yang F., Xue L., Han Z. et al. Vaspin alleviates myocardial ischaemia/reperfusion injury via activating autophagic flux and restoring lysosomal function. Biochem. Biophys. Res. Commun, 2018, vol. 503 (2), pp. 501–507. DOI: 10.1016/j.bbrc.2018.05.004
15. Liu S., Li X., Wu Y. et al. Effects of vaspin on pancreatic β cell secretion via PI3K/Akt and NF-κB signaling pathways. PLoS One, 2017, vol. 12. e0189722. DOI: 10.1371/journal.pone.0189722
16. Luo X., Li K., Zhang C. et al. Central administration of vaspin inhibits glucose production and augments hepatic insulin signaling in high-fat-diet-fed rat. Int. J. Obes., 2016, vol. 40, pp. 947–954.
17. Feng R., Li Y., Wang C. et al. Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: A meta-analysis. Diabetes Res. Clin. Pract, 2014, vol. 106 (1), pp. 88–94.
18. Nicholson T., Church C., Tsintzas K. et al. Vaspin promotes insulin sensitivity in elderly muscle and is upregulated in obesity. J Endocrinol, 2019, vol. 241 (1), pp. 31–43. DOI: 10.1530/JOE-18-0528
19. Kloting N., Berndt J., Kralisch S. et al. Vaspin gene expression in human adipose tissue:Association with obesity and type 2diabetes. Biochem. Biophys. Res. Com, 2006, vol. 339, pp. 430–436.
20. Liu Y., Gong M., Liu S. et al. Effects of blood glucose on vaspin secretion in patients with gestational diabetes mellitus. Gynecol. Endocrinol, 2020, vol. 37 (3), pp. 221–224.
21. Ji M., Li Y., Liu Y. et al. Vaspin ameliorates cardiac remodeling by suppressing phosphoinositide 3-kinase/protein kinase b pathway to improve oxidative stress in heart failure rats. J. Cardiovasc. Pharmacol, 2022, vol. 80 (3), pp. 442–452.
22. Jung C., Lee W., Hwang J. Vaspin increases nitric oxide bioavailability through the reduction of asymmetric dimethylarginine in vascular endothelial cells. PLoS One, 2012, vol. 7. e52346. DOI: 10.1371/journal.pone.0052346
23. Jung H., Jung C. The role of anti-inflammatory adipokines in cardiometabolic disorders: moving beyond adiponectin. Int. J. Mol. Sci, 2021, vol. 22 (24), p. 13529. DOI: 10.3390/ijms222413529
24. Aliyeva A.M., Reznik E.V., Baykova I.E. et al. Vaspin as a cardiovascular biological marker. RMZH, 2023, no. 4 (in Russ.).
25. Kuznetsova L.A., Shpakov O.A. Adipokines and their possible role in obesity and type 2 diabetes mellitus. Saratovskiy nauchno-meditsinskiy zhurnal, 2018, vol. 14, no. 2 (in Russ.).
26. Bozkurt Doğan Ş., Öngöz D.F., Ballı U. et al. Levels of vaspin and omentin-1 in gingival crevicular fluid as potential markers of inflammation in patients with chronic periodontitis and type 2 diabetes mellitus. J. Oral. Sci, 2016, vol. 58 (3), pp. 379–389.
27. Dimova R., Tankova T., Kirilov G. Is vaspin associated with cardiometabolic status and autonomic function in the early stages of impaired glucose tolerance? Diabetol. Metab. Syndr, 2016, no. 8, p. 46 (in Russ.). DOI: 10.1186/s13098-016-0165-1.
28. Sato K., Shirai R., Yamaguchi M. Anti-atherogenic effects of vaspin on human aortic smooth muscle cell/macrophage responses and hyper-lipidemic mouse plaque phenotype. Int. J. Mol. Sci, 2018, vol. 19, p. 1732. DOI: 10.3390/ijms19061732
29. Kempf K., Rose B., Illig T., Rathmann W., Strassburger K., Thorand B. et al. Vaspin (SERPINA12) genotypes and the risk of developing type 2 diabetes: results from the MONICA/KORA studies. Exp. Clin. Endocrinol. Diabetes, 2010, vol. 118 (03), p. 184 (in Russ.). DOI: 10.1055/s-2008-1081499
30. Hosseini M., Nezhadali M., Hedayati M. Association of vaspin rs2236242 gene polymorphism with serum vaspin level, insulin resistance and diabetes in an Iranian diabetic/pre-diabetic population. J. Med. Biochem, 2021, vol. 40 (1), pp. 33–40. DOI: 10.5937/jomb0-24671
31. Teshigawara S., Wada J., Hida K. et al. Serum vaspin concentrations are closely related to insulin resistance, and rs77060950 at SERPINA12 genetically defines distinct group with higher serum levels in Japanese population. J. Clin. Endocrinol. Metab, 2012, vol. 97 (7), pp. E1202-7. DOI: 10.1210/jc.2011-3297
32. Recinella L., Orlando G., Ferrante C. Adipokines: new potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases. Front. Physiol., 2020, vol. 11. 578966. DOI: 10.3389/fphys.2020.578966
33. Voronkova N.V., Shakirova K.V., Mikhaylova I.V. et al. Rhythm and conduction disturbances in different locations and depths of acute myocardial infarction according to 24-hour ECG monitoring. Acta Medica Eurasica, 2015, no. 2 (in Russ.).